Technology Innovation Institute’s Secure Systems Research Centre Partners with Purdue University on Game-Changing UAV Security Project
10.3.2021 13:29:00 EET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Purdue University, a world-renowned US-based public research university. The two entities are collaborating on a three-year sophisticated cybersecurity project to ensure Unmanned Aerial Vehicles (UAVs) can be used safely and efficiently in urban operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005409/en/
Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) - (Photo: AETOSWire)
Secure Systems Research Centre is one of initial seven dedicated research centres at TII. The research collaboration with Purdue University, titled ‘Cybersecurity for UAS Operations in Urban Environment’, includes the study of security and resilience in cyber-physical and autonomous systems. The project examines safety challenges that Unmanned Aerial Systems (UASs) experience in operating environments. These systems and vehicles are vulnerable to sophisticated cyberattacks in terms of communication, navigation, surveillance, and command and control. The outcome of this research will help other research at Secure Systems Research Centre in the future.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is becoming increasingly complex. This is evidenced by the rising number of cyberattacks and surveillance breaches that occur daily. We must regain control over critical digital systems. We are optimistic that the research outcomes at TII’s Secure Systems Research Centre will allow us to gain the upper hand in the fight against these malicious attacks.”
He added: “We are delighted to have the Purdue Team led by Prof. Inseok Hwang of School of Aeronautics and Astronautics partner on making cyber-physical and autonomous systems secure and resilient to malware using their state of the art autonomous drone testing facility. This will enable commercial autonomous drones and robots growth in the UAE and worldwide, opening new opportunities to enterprises and making their use safer for all people.”
A multidisciplinary group of researchers from Purdue University will join forces with TII’s Secure Systems Research Centre team.
The research project comprises four phases of development. First, it will carry out a modelling and analysis of UAS security. Second, it will develop algorithms and methodologies for high-assurance autonomy. Third, it will construct an experimental environment and work to simulate safe and secure urban UAS operations. Finally, it will test and validate mitigation strategies in a scaled, mixed-reality testbed.
This three-year project is led by Prof. Inseok Hwang as the principal investigator. Prof. Hwang is assisted on this project by two co-researchers from Purdue University – Prof. James Goppert, a visiting assistant professor at the School of Aeronautics and Astronautics and managing director of the UAS Research and Test Facility; and Prof. Dongyan Xu, the Samuel D. Conte Professor of Computer Science and Director of CERIAS (Center for Education and Research in Information Assurance and Security), Purdue’s cybersecurity research and education center.
Prof. Hwang will assess potential cyberattacks on the systems, Prof. Xu will conduct resource-efficient encryption, multi-UAS communications, and other research from the cyber perspective while Prof. Goppert will test the drones in a special mixed reality environment he will design and build.
Prof. Hwang said: “This landmark project comes at a time of growing reliance on UASs across various sectors – from security to medicine and logistics, and everything in between. We are confident that our partnership will translate into global wins for the international community and lead to many more research milestones in the years to come.”
For more information, please visit www.tii.ae and https://securesystems.tii.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005409/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
